How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

255 results for

Alpha-Hydroxy acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. MÄ’ Device for At-Home Skin Rejuvenation

to make no changes in their existing skincare regime, other than use of the study products, during the study period. If female, must be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Exclusion Criteria: Subjects who currently use or have used in the prior 30 days any skin products that contain alpha hydroxy (...) acids (AHA) e.g. glycolic, lactic, citric, or mandelic acid containing products or retinol/tretinoin containing products or exfoliating washes, masks or scrubs or other micro-dermabrasion skin care products on the treatment areas. Subjects who are unwilling to maintain their daily skin care regimen for the duration of the study. Subjects who have any skin pathology or condition that could interfere with the evaluation i.e. personal or family history of skin cancer, rosacea and/or requires the use

2016 Clinical Trials

62. Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

., human immunodeficiency virus [ HIV], systemic malignancy, graft host disease, etc.) or is taking medications that suppress the immune system. Has experienced an unsuccessful outcome from previous topical diclofenac sodium therapy. Has a history of sensitivity to any of the ingredients in the test articles or other excipients in the test or reference drug. Has signs or symptoms consistent with the aspirin (ASA) triad. Has used topical medications: corticosteroids, alpha hydroxy acids (e.g., glycolic (...) acid, lactic acid, etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >2%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, aminolevulinic acid (ALA) or prescription retinoids (e.g., tazarotene, adapalene, tretinoin), over-the-counter (OTC) products labeled as scrubs of any kind which are used to smooth the skin (as they contain some form of exfoliant such as nut shells, coffee grounds, polymer particles, etc.) within the selected treatment area (face or bald scalp) within one month

2016 Clinical Trials

63. Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

, imiquimod, 5-fluorouracil, or diclofenac on their face within 3 months Prescription strength skin lightening products (e.g. 4% hydroquinone, tretinoin, alpha hydroxy acid (AHA), beta hydroxy acid (BHA) and polyhydroxy acids, 15% or 20% azelaic acid, 4-hydroxyanisole alone or in combination with tretinoin, etc.) within 3 months Any non-prescription cosmetic anti-wrinkle, skin lightening products, or any other product or topical or systemic medication known to affect skin aging or dyshcromia (products (...) containing alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250, gigawhite, lemon juice extract (topically), emblica extract, etc.) within 2 weeks Have undergone plastic surgery, Dermabrasion (deep skin peel), a deep chemical peel or ablative laser resurfacing of the face and neck within 12 months Had facial treatment with a botulinum toxin base injectable (Botox), injectable fillers, or a fat transfer within 6 months Contacts

2016 Clinical Trials

64. TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

. A subject with an active bacterial, fungal, or viral infection in the treatment area. A subject with known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family sedation medication. A subject with known allergy or sensitivity to propylene glycol or any other ingredient of topical TR-987 or placebo. A subject receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or E

2016 Clinical Trials

65. A Single-Center 2-Arm Study for Lentigines on the Hands

, within 6 months of study participation. Use of topical medications on the hands, such as antibiotics, benzoyl peroxide, retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing dihydroxyacetone or alpha-hydroxy with concentration > 8%, within 1 month of participation. History of malignant tumors in the target area. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles. Pregnant. Having an infection, dermatitis, or a rash in the treatment area (...) . Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler to the treatment area during the study. Exclusion Criteria: Participation in a clinical trial of another device or drug in the target area within 6 months prior to enrollment or during the study. Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser or light-based procedures or surgery. Systemic use of retinoid, such as isotretinoin

2016 Clinical Trials

66. Topical Itraconazole in Treating Patients With Basal Cell Cancer

; specifically these include the topical use to the study tumors of: glucocorticoids (ii) retinoids (e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically (iii) alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod; also - treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling within 60 days to starting study medication Contacts

2016 Clinical Trials

67. Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

topical over-the-counter preparations for acne treatment Use of the following on the face within 1 week before Screening/Baseline: Phototherapy devices for acne (e.g., ClearLightTM) Medicated cleansers including adhesive cleansing strips Cosmetic procedures (i.e., facials, peeling, comedone extraction) and alpha-hydroxy/glycolic acid Receipt of any drug as part of a research study within 30 days. Female patients taking hormonal contraceptives or oral estrogen for less than three months and those (...) Systemic steroids Systemic antibiotics Systemic anti-inflammatory agents (the use of acetylsalicylic acid for prophylactic use up to 325 mg/day is allowed, provided that the patient is on a stable dose and the regimen will remain constant throughout the study). Acetaminophen will be allowed during the study with a maximum dose of 1g (i.e., 1000 mg) twice daily and for a maximum of 3 consecutive days (its use is not allowed within 1 week of each visit). Systemic treatment for acne vulgaris (other than

2016 Clinical Trials

68. Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy

with a double enterostomy on plasma levels of FGF19 [ Time Frame: Week 7 ] Secondary Outcome Measures : Effect of chyme reinfusion in patients with a double enterostomy on plasma bile salt levels [ Time Frame: Week 7 ] Measurement of bile salt Assessment of 7-alpha-hydroxy-4-cholesten-3-one (C4) plasma levels [ Time Frame: Week 7 ] Assessment of bile salt composition in plasma [ Time Frame: Week 7 ] Assessment of microbiotic profiling [ Time Frame: Week 7 ] Assessment of citrulline plasma levels [ Time (...) Frame: Week 7 ] Assessment of intestinal-fatty acid binding protein (I-FABP) plasma levels [ Time Frame: Week 7 ] Assessment of smooth muscle specific (SM) 22 plasma levels [ Time Frame: Week 7 ] Effect of chyme reinfusion in patients with a double enterostomy on liver function [ Time Frame: Week 7 ] Assessment of lipopolysaccharide binding protein (LBP) plasma levels [ Time Frame: Week 7 ] Assessment of plasma levels of inflammatory cytokines interleukin-6 (IL-6) [ Time Frame: Week 7 ] Assessment

2016 Clinical Trials

69. Silk'n HST Device Usability and Self Selection Study

, (e.g., aspirins, ibuprofens, acetaminophen), tetracyclines, phenothiazines, thiazide, diuretics, sulfonyluraes, sulfonamides, DTIC, fluorouracil, vinblastine, griseofulvin, Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A®, Accutane® and/or topical retinoids. Subject with abnormal skin conditions caused by diabetes, for example, or other systemic or metabolic diseases. Subject currently or has recently been treated with Alpha-Hydroxi Acids (AHAs), Beta-Hydroxi Acids (BHAs), Retin-A® (...) , topical retinoids or azelaic acid. Subject has been treated with Accutane® (isotretinoin) within the past 6 months. Subject has been on a steroid regimen within the past 3 months. Subject has a history of herpes outbreaks in the area of treatment. Subject suffers from epilepsy. Subject with an active implant, such as a pacemaker, incontinence device, insulin pump, etc. Subject with a disease related to photosensitivity, such as porphyria, polymorphic light eruption, solar urticaria, lupus, etc

2016 Clinical Trials

70. A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines

topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral areas within 7 days prior to or during the study period, other than the study products A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their perioral areas within 30 days prior to or during the study period A patient using any topical tretinoin product or derivative on their perioral areas within 12 (...) Information Go to Layout table for additonal information Responsible Party: Corey S. Maas, M.D., Principal Investigator, The Maas Clinic ClinicalTrials.gov Identifier: Other Study ID Numbers: RSB-2015 First Posted: June 29, 2016 Last Update Posted: June 29, 2016 Last Verified: June 2016 Additional relevant MeSH terms: Layout table for MeSH terms Hyaluronic Acid Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Viscosupplements Protective Agents

2016 Clinical Trials

71. Skin Imaging to Assess the Effects of Tretinoin Cream and Skin Smoothing Laser Using Optic Imaging Technologies

of age or older - Skin type scale I to III Exclusion Criteria: Large amount of dark, coarse hair on the arms History of allergies to alpha hydroxy acids (AHAs), retinoids, soaps, fragrances, sunscreens or Latex Currently using over-the-counter AHA or retinol within one month or prescription retinoid within three months of the start of the study. History of skin cancer, including squamous or basal cell carcinoma at the treatment site or history of malignant melanoma. History of diabetes Currently

2015 Clinical Trials

72. Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms and spermicide) and abstinence. Subjects willing to refrain from the use of topical products containing alpha-hydroxy acids, retinoic acid, retinol, salicylic acid, and vitamins C/D (or their derivatives) in the treatment area 7 Days prior to and during the entire study period Exclusion Criteria: Known hypersensitivity, prior allergic reaction, or prior chest treatment with ingenol mebutate gel (...) area listed during the duration of the study. Within 3 months of study entry topical treatment in the treatment area for actinic keratosis including, but not limited to imiquimond, 5- fluorouracil, diclofenac or liquid nitrogen. Within 6 months of study entry treatments with Poly-L-lactic acid (PLLA; Sculptra Aesthetic) that may interfere with the evaluation of the treatment area. Within 7 days of study entry use of self-tanners, excessive exposure to sunlight or artificial UV light (e.g.: use

2015 Clinical Trials

73. Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery

Criteria Inclusion Criteria: Female subjects with age range 18-60 years; Subject with hypertrophic scar from abdominal surgery for at least 3 months; Discontinued using oral isotretinoin for 6 months, alpha hydroxy acid or topical retinoic acid for 3 months Exclusion Criteria: Subject who has skin Infection, photosensitive dermatosis or inflammatory acne on the treated area; Subject who smoke cigarette; Subject who was treated with Intralesional corticosteroid Contacts and Locations Go to Information

2015 Clinical Trials

74. Medicinal Plants for the Treatment of Acne Vulgaris: A Review of Recent Evidences Full Text available with Trip Pro

Medicinal Plants for the Treatment of Acne Vulgaris: A Review of Recent Evidences Acne vulgaris affects about 85% of teenagers and may continue to adulthood. There are about two million visits to physicians per year for teenagers and the direct cost of acne treatment in the US exceeds $1 billion per year.A wide variety of treatment regimens exist for acne vulgaris including benzoil peroxide, retinoids, isotretinoids, keratolytic soaps, alpha hydroxy acids, azelaic acid, salicilic acid as well

2015 Jundishapur journal of microbiology

75. Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

dehydrogenase (DPD) enzyme deficiency. Subject used topical creams, lotions, or gels of any kind within the selected Treatment Area within one day prior to entry into the study. Subject has used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid, etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area

2015 Clinical Trials

76. A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines

or over the counter) medicated creams, lotions, gels, balms, powders, etc. on the treatment areas during the study period A patient receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral or lateral canthal areas within 7 days prior to or during the study period, other than the study products A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment (...) A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines - Full Text

2010 Clinical Trials

77. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Full Text available with Trip Pro

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Di-alpha hydroxy bile salt, sodium chenodeoxycholate (CDC), and bile acid binding have unclear effects on colonic transit in health and disease.We performed 2 randomized, double-blind, placebo-controlled studies. In healthy volunteers (20 per group), we evaluated the effects of oral placebo, 500 mg, or 1000 mg of CDC (delayed-release, each given for 4 days) on gastrointestinal (...) and colonic transit. A second trial compared the effects of colesevelam (1.875 g, twice daily) versus placebo in 24 patients (12 per group) with diarrhea-predominant irritable bowel syndrome (IBS-D) on transit, daily bowel frequency and consistency, and colonic mucosal permeability. Serum fasting 7alpha-hydroxy-4-cholesten-3-one (7alphaC4) was measured to screen for bile acid malabsorption. Effects of treatments on transit were compared using analysis of covariance with body mass index and 7alphaC4

2010 Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Controlled trial quality: uncertain

78. Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

) divided by 10^3. Participants with fecal bile acid concentration and their average pre-first dose and average post-first dose were reported. Mean Serum 7- Alpha-hydroxy-4-cholesten-3-one (C4) Concentration [ Time Frame: Day -1 to Day 15 ] Serum 7- alpha-hydroxy-4-cholesten-3-one (C4) concentrations were reported. Number of Participants With Stool Hardness Using Bristol Stool Chart [ Time Frame: Day -2 to Day 14 ] Stool hardness was assessed after each evacuation using the bristol stool chart (...) . Secondary Outcome Measures : Average Total Fecal Bile Acid (FBA) Concentration [ Time Frame: Day -2 up to Day 14 ] Stool samples for the determination of total FBA were collected in 48-hour windows from 48 hours before dosing on Day 1 through Day 14. The average of daily total FBA excretion is calculated before (Day -1 and Day -2) as the first pre dose of IMP and after (Day 1-12) as the first post-dose of IMP. The FBA is calculated as Total FBA (micromoles) = FBA (micromol per liter) * weight (grams

2014 Clinical Trials

79. A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome

cholesterol, low-density lipoprotein cholesterol [LDL-C]) will be assessed. Change From Baseline in Bile Acid Synthesis [ Time Frame: Week 18, 22, 48 and thereafter every 12 weeks until Week 96 ] Change from baseline in bile acid synthesis (serum 7 alpha-hydroxy-4-cholesten-3-one [7alphaC4]) will be assessed. Pruritus Respose Rate as Measured by Observer ItchRO/Patient ItchRO [ Time Frame: Weeks 18, 48, 60, 72, 84, 96 and 100 ] Pruritus will be assessed using the Itch caregiver (for participants between (...) -Blind, Placebo-Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Alagille Syndrome Actual Study Start Date : October 28, 2014 Estimated Primary Completion Date : December 31, 2019 Estimated Study Completion Date : December 31, 2019 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: LUM001 LUM001

2014 Clinical Trials

80. Paraneoplastic Diseases (Diagnosis)

of AI includes hydration of the skin and prevention of evaporation. This is achieved through the topical application of alpha-hydroxy acids (eg, lactic, glycolic, and pyruvic acids) and emollients (eg, urea creams, propylene glycol). Topical corticosteroids are not useful. Acrokeratosis paraneoplastica (Bazex syndrome) In 1965, Bazex described the development of eczematous or psoriasiform plaques on acral surfaces in association with an underlying cancer. The clinical features of Bazex syndrome (...) of the lung, and positive anti-HU antibody titer. (a) Peripheral nerve in longitudinal section stained with Luxol fast blue-periodic acid-Schiff (PAS) showing scattered wallerian degeneration (arrowheads). (b) Low-power view of a paravertebral sympathetic ganglion stained with hematoxylin and eosin (H&E). Arrowhead indicates perivascular mononuclear infiltrates. (c) High-power view of the same sympathetic ganglion showing degenerating neurons (single arrowheads) and mononuclear infiltrates (double

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>